Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · IEX Real-Time Price · USD
1.610
-0.060 (-3.59%)
At close: May 1, 2024, 4:00 PM
1.580
-0.030 (-1.86%)
After-hours: May 1, 2024, 7:02 PM EDT

Enlivex Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current2023202220212020201920182017201620152014
Market Capitalization
30507211587437155583
Market Cap Growth
--30.73%-36.72%31.51%2372.48%36.23%-65.49%-49.36%-73.13%-33.70%-
Enterprise Value
323223051-7-7-2123650
PE Ratio
-1.73-1.73-2.33-7.92-7.37-0.37-0.61-2.99-5.14-3.58-11.83
PB Ratio
0.991.671.271.352.460.310.270.885.273.072.71
P/FCF Ratio
-2.13-2.13-2.26-5.98-7.24-0.49-0.71-3.08-6.24-4.14-18.58
P/OCF Ratio
-2.13-2.13-3.03-6.53-7.91-0.50-0.82-3.25-6.76-4.16-18.84
EV/EBITDA Ratio
-0.80-0.80-0.89-1.62-4.460.731.750.74-4.31-2.33-7.19
EV/EBIT Ratio
-0.78-0.78-0.86-1.58-4.350.701.700.71-4.22-2.33-7.19
EV/FCF Ratio
-0.97-0.97-0.69-1.59-4.270.911.980.62-4.97-2.69-11.28
Debt / Equity Ratio
----0.030.30-----
Debt / EBITDA Ratio
-----0.10-0.38-----
Debt / FCF Ratio
-----0.10-0.47-----
Quick Ratio
4.514.517.6017.838.442.268.8413.074.778.1114.42
Current Ratio
5.575.577.9218.328.722.759.1013.104.848.1114.42
Interest Coverage
---4.90----1413.00-5.77-32.47--
Return on Equity (ROE)
-71.00%-71.00%-46.70%-16.40%-37.50%-69.70%-46.60%-43.10%-27.80%-65.90%-45.50%
Return on Assets (ROA)
-59.10%-59.10%-40.60%-15.10%-32.20%-49.00%-41.20%-36.80%-24.00%-60.70%-42.20%
Return on Capital (ROIC)
-97.71%-97.71%-45.38%-22.68%-26.69%-58.70%-54.60%-25.56%-100.43%-86.30%-23.08%
Earnings Yield
-97.12%-57.89%-42.84%-12.63%-13.57%-266.33%-164.02%-33.41%-19.45%-27.90%-8.45%
FCF Yield
-78.94%-47.05%-44.24%-16.73%-13.80%-205.20%-140.04%-32.48%-16.03%-24.14%-5.38%
Buyback Yield / Dilution
-0.98%-0.98%-3.00%-35.62%-52.25%-146.47%-2.43%-2.03%-843.79%-16.08%-45.55%
Total Shareholder Return
-0.98%-0.98%-3.00%-35.62%-52.25%-146.47%-2.43%-2.03%-843.79%-16.08%-45.55%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).